Leukemia - Issue - nature.com science feeds

Commentary on Perrone et al.: ‘Vitamin C: not for breakfast anymore…if you have myeloma’

R D Harvey — 2009-11-11

Commentary on Perrone et al.: ‘Vitamin C: not for breakfast anymore…if you have myeloma’

Leukemia 23, 1939 (November 2009). doi:10.1038/leu.2009.128

Authors: R D Harvey, J Nettles, B Wang, S-Y Sun & S Lonial

The molecular characterization and clinical management of multiple myeloma in the post-genome era

Y Zhou — 2009-11-11

The molecular characterization and clinical management of multiple myeloma in the post-genome era

Leukemia 23, 1941 (November 2009). doi:10.1038/leu.2009.160

Authors: Y Zhou, B Barlogie & J D Shaughnessy

Harmonization of molecular monitoring of CML therapy in Europe

M C Müller — 2009-11-11

Harmonization of molecular monitoring of CML therapy in Europe

Leukemia 23, 1957 (November 2009). doi:10.1038/leu.2009.168

Authors: M C Müller, N C P Cross, P Erben, T Schenk, B Hanfstein, T Ernst, R Hehlmann, S Branford, G Saglio & A Hochhaus

Proteasome inhibitors in the treatment of multiple myeloma

J J Shah — 2009-11-11

Proteasome inhibitors in the treatment of multiple myeloma

Leukemia 23, 1964 (November 2009). doi:10.1038/leu.2009.173

Authors: J J Shah & R Z Orlowski

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

A Österborg — 2009-11-11

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

Leukemia 23, 1980 (November 2009). doi:10.1038/leu.2009.146

Authors: A Österborg, R Foà, R F Bezares, C Dearden, M J S Dyer, C Geisler, T S Lin, M Montillo, M H J van Oers, C-M Wendtner & K R Rai

PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study

J Familiades — 2009-11-11

PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study

Leukemia 23, 1989 (November 2009). doi:10.1038/leu.2009.135

Authors: J Familiades, M Bousquet, M Lafage-Pochitaloff, M-C Béné, K Beldjord, J De Vos, N Dastugue, E Coyaud, S Struski, C Quelen, N Prade-Houdellier, S Dobbelstein, J-M Cayuela, J Soulier, N Grardel, C Preudhomme, H Cavé, O Blanchet, V Lhéritier, A Delannoy, Y Chalandon, N Ifrah, A Pigneux, P Brousset, E A Macintyre, F Huguet, H Dombret, C Broccardo & É Delabesse

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

A Davies — 2009-11-11

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

Leukemia 23, 1999 (November 2009). doi:10.1038/leu.2009.166

Authors: A Davies, N E Jordanides, A Giannoudis, C M Lucas, S Hatziieremia, R J Harris, H G Jørgensen, T L Holyoake, M Pirmohamed, R E Clark & J C Mountford

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

S Böttcher — 2009-11-11

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

Leukemia 23, 2007 (November 2009). doi:10.1038/leu.2009.140

Authors: S Böttcher, S Stilgenbauer, R Busch, M Brüggemann, T Raff, C Pott, K Fischer, G Fingerle-Rowson, H Döhner, M Hallek, M Kneba & M Ritgen

Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia

A Farfsing — 2009-11-11

Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia

Leukemia 23, 2018 (November 2009). doi:10.1038/leu.2009.144

Authors: A Farfsing, F Engel, M Seiffert, E Hartmann, G Ott, A Rosenwald, S Stilgenbauer, H Döhner, M Boutros, P Lichter & A Pscherer

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study

A Cortelezzi — 2009-11-11

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study

Leukemia 23, 2027 (November 2009). doi:10.1038/leu.2009.148

Authors: A Cortelezzi, M C Pasquini, A Gardellini, U Gianelli, A Bossi, G Reda, B Sarina, P Musto, W Barcellini, A Neri & G L Deliliers

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia

K D Mason — 2009-11-11

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia

Leukemia 23, 2034 (November 2009). doi:10.1038/leu.2009.151

Authors: K D Mason, S L Khaw, K C Rayeroux, E Chew, E F Lee, W D Fairlie, A P Grigg, J F Seymour, J Szer, D C S Huang & A W Roberts

Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4+ very small embryonic-like stem cells

D M Shin — 2009-11-11

Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4+ very small embryonic-like stem cells

Leukemia 23, 2042 (November 2009). doi:10.1038/leu.2009.153

Authors: D M Shin, E K Zuba-Surma, W Wu, J Ratajczak, M Wysoczynski, M Z Ratajczak & M Kucia

Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes

H M Lee — 2009-11-11

Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes

Leukemia 23, 2052 (November 2009). doi:10.1038/leu.2009.158

Authors: H M Lee, W Wu, M Wysoczynski, R Liu, E K Zuba-Surma, M Kucia, J Ratajczak & M Z Ratajczak

The TLR1/2 agonist PAM3CSK4 instructs commitment of human hematopoietic stem cells to a myeloid cell fate

K De Luca — 2009-11-11

The TLR1/2 agonist PAM3CSK4 instructs commitment of human hematopoietic stem cells to a myeloid cell fate

Leukemia 23, 2063 (November 2009). doi:10.1038/leu.2009.155

Authors: K De Luca, V Frances-Duvert, M-J Asensio, R Ihsani, E Debien, M Taillardet, E Verhoeyen, C Bella, S Lantheaume, L Genestier & T Defrance

Defining origins of malignant B cells: a new circulating normal human IgM+D+ B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population

N Weston-Bell — 2009-11-11

Defining origins of malignant B cells: a new circulating normal human IgM+D+ B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population

Leukemia 23, 2075 (November 2009). doi:10.1038/leu.2009.178

Authors: N Weston-Bell, M Townsend, G Di Genova, F Forconi & S S Sahota

Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1

J-M Terme — 2009-11-11

Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1

Leukemia 23, 2081 (November 2009). doi:10.1038/leu.2009.131

Authors: J-M Terme, V Mocquet, A-S Kuhlmann, L Zane, F Mortreux, E Wattel, M Duc Dodon & P Jalinot

Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells

H Hasegawa — 2009-11-11

Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells

Leukemia 23, 2090 (November 2009). doi:10.1038/leu.2009.171

Authors: H Hasegawa, Y Yamada, H Iha, K Tsukasaki, K Nagai, S Atogami, K Sugahara, K Tsuruda, A Ishizaki & S Kamihira

IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing

G Regis — 2009-11-11

IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing

Leukemia 23, 2102 (November 2009). doi:10.1038/leu.2009.139

Authors: G Regis, L Icardi, L Conti, R Chiarle, R Piva, M Giovarelli, V Poli & F Novelli

A robust xenotransplantation model for acute myeloid leukemia

P V Sanchez — 2009-11-11

A robust xenotransplantation model for acute myeloid leukemia

Leukemia 23, 2109 (November 2009). doi:10.1038/leu.2009.143

Authors: P V Sanchez, R L Perry, J E Sarry, A E Perl, K Murphy, C R Swider, A Bagg, J K Choi, J A Biegel, G Danet-Desnoyers & M Carroll

Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles

M Plander — 2009-11-11

Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles

Leukemia 23, 2118 (November 2009). doi:10.1038/leu.2009.145

Authors: M Plander, S Seegers, P Ugocsai, S Diermeier-Daucher, J Iványi, G Schmitz, F Hofstädter, S Schwarz, E Orsó, R Knüchel & G Brockhoff

Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma

S Eckerle — 2009-11-11

Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma

Leukemia 23, 2129 (November 2009). doi:10.1038/leu.2009.161

Authors: S Eckerle, V Brune, C Döring, E Tiacci, V Bohle, C Sundström, R Kodet, M Paulli, B Falini, W Klapper, A B Chaubert, K Willenbrock, D Metzler, A Bräuninger, R Küppers & M-L Hansmann

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients

S Colucci — 2009-11-11

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients

Leukemia 23, 2139 (November 2009). doi:10.1038/leu.2009.136

Authors: S Colucci, G Brunetti, G Mori, A Oranger, M Centonze, C Mori, F P Cantatore, R Tamma, R Rizzi, V Liso, A Zallone & M Grano

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

M A Dimopoulos — 2009-11-11

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

Leukemia 23, 2147 (November 2009). doi:10.1038/leu.2009.147

Authors: M A Dimopoulos, C Chen, A Spencer, R Niesvizky, M Attal, E A Stadtmauer, M T Petrucci, Z Yu, M Olesnyckyj, J B Zeldis, R D Knight & D M Weber

Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33)

I Nagel — 2009-11-11

Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33)

Leukemia 23, 2153 (November 2009). doi:10.1038/leu.2009.149

Authors: I Nagel, S Bug, H Tönnies, O Ammerpohl, J Richter, I Vater, E Callet-Bauchu, M J Calasanz, J A Martinez-Climent, C Bastard, M Salido, E Schroers, J I Martin-Subero, S Gesk, L Harder, A Majid, M J S Dyer & R Siebert

Imatinib mesylate causes growth plate closure in vivo

K Vandyke — 2009-11-11

Imatinib mesylate causes growth plate closure in vivo

Leukemia 23, 2155 (November 2009). doi:10.1038/leu.2009.150

Authors: K Vandyke, A L Dewar, S Fitter, D Menicanin, L B To, T P Hughes & A C W Zannettino

Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia

R Bhat — 2009-11-11

Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia

Leukemia 23, 2159 (November 2009). doi:10.1038/leu.2009.159

Authors: R Bhat, S Malinge, A S Gamis, A D Sorrell, J M Hilden, R P Ketterling, E Paietta, M S Tallman & J D Crispino

B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures

I Del Giudice — 2009-11-11

B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures

Leukemia 23, 2160 (November 2009). doi:10.1038/leu.2009.137

Authors: I Del Giudice, N Osuji, T Dexter, V Brito-Babapulle, N Parry-Jones, S Chiaretti, M Messina, G Morgan, D Catovsky & E Matutes

Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis

K Eberhart — 2009-11-11

Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis

Leukemia 23, 2167 (November 2009). doi:10.1038/leu.2009.154

Authors: K Eberhart, K Renner, I Ritter, M Kastenberger, K Singer, C Hellerbrand, M Kreutz, R Kofler & P J Oefner

Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D3

C Nishioka — 2009-11-11

Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D3

Leukemia 23, 2171 (November 2009). doi:10.1038/leu.2009.152

Authors: C Nishioka, T Ikezoe, J Yang & A Yokoyama

miR-34b/miR-34c: a regulator of TCL1 expression in 11q− chronic lymphocytic leukaemia?

B Cardinaud — 2009-11-11

miR-34b/miR-34c: a regulator of TCL1 expression in 11q− chronic lymphocytic leukaemia?

Leukemia 23, 2174 (November 2009). doi:10.1038/leu.2009.125

Authors: B Cardinaud, C Moreilhon, B Marcet, K Robbe-Sermesant, K LeBrigand, B Mari, V Eclache, F Cymbalista, S Raynaud & P Barbry

Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma

M Roussou — 2009-11-11

Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma

Leukemia 23, 2177 (November 2009). doi:10.1038/leu.2009.130

Authors: M Roussou, A Tasidou, M A Dimopoulos, E Kastritis, M Migkou, D Christoulas, M Gavriatopoulou, F Zagouri, C Matsouka, D Anagnostou & E Terpos

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma

D Gutman — 2009-11-11

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma

Leukemia 23, 2181 (November 2009). doi:10.1038/leu.2009.123

Authors: D Gutman, A A Morales & L H Boise

Mutations of ASXL1 gene in myeloproliferative neoplasms

N Carbuccia — 2009-11-11

Mutations of ASXL1 gene in myeloproliferative neoplasms

Leukemia 23, 2183 (November 2009). doi:10.1038/leu.2009.141

Authors: N Carbuccia, A Murati, V Trouplin, M Brecqueville, J Adélaïde, J Rey, W Vainchenker, O A Bernard, M Chaffanet, N Vey, D Birnbaum & M J Mozziconacci

HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation

H Akl — 2009-11-11

HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation

Leukemia 23, 2187 (November 2009). doi:10.1038/leu.2009.201

Authors: H Akl, B M Badran, N El Zein, F Bex, C Sotiriou, K E Willard-Gallo, A Burny & P Martiat